Search

Clobazam

[A256868] Additionally, clobazam is believed to be a partial agonist to the GABA_A receptor rather than non-selective full receptor agonists like 1,4-benzodiazepines, thus potentially explaining … [A256913] Unlike older 1,4-benzodiazepines, clobazam has a better side-effects profile, particularly less sedative and amnesic effects.

Ramucirumab

By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, … Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells.

Telbivudine

Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus.

LV-SMENP Vaccine

LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which

Icotinib

. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

Taberminogene vadenovec

EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC). … Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs

Navarixin

Navarixin has been investigated for the treatment of Asthma.

Cibenzoline

COVID19 s-vax loaded autologous dendritic cell vaccine

The rationale is that loading a DC cell with SARS-Cov-2 antigens and administering it as a vaccine can induce a more prolific immune response. … DC-based vaccines are currently used in cancer therapeutics, and are being tested for COVID-19.

CoVac-1

Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].